Left ventricular ejection fraction data from the JAVELIN Ovarian 200 trial showed low cardiotoxicity in patients with ovarian cancer treated with avelumab, avelumab plus PLD, or PLD.
Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.
A study determined oncology nurses are aware of biomarker testing and targeted therapy for ovarian cancer but seemed less aware of their specific details.